Kymera Therapeutics (KYMR) Set to Announce Quarterly Earnings on Thursday

Kymera Therapeutics (NASDAQ:KYMR) will issue its quarterly earnings data before the market opens on Thursday, May 2nd. Analysts expect the company to announce earnings of ($0.73) per share for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings data on Thursday, February 22nd. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.19. The business had revenue of $47.90 million during the quarter, compared to the consensus estimate of $41.94 million. Kymera Therapeutics had a negative return on equity of 34.83% and a negative net margin of 187.00%. Kymera Therapeutics’s quarterly revenue was up 197.5% on a year-over-year basis. During the same period last year, the company earned ($0.60) earnings per share. On average, analysts expect Kymera Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Kymera Therapeutics Price Performance

NASDAQ:KYMR traded down $0.69 during trading hours on Tuesday, reaching $33.97. 119,213 shares of the stock were exchanged, compared to its average volume of 719,032. The firm has a 50 day moving average of $38.83 and a 200 day moving average of $28.91. Kymera Therapeutics has a twelve month low of $9.60 and a twelve month high of $45.31. The stock has a market cap of $2.08 billion, a PE ratio of -13.75 and a beta of 2.27.

Insider Buying and Selling

In related news, CFO Bruce N. Jacobs sold 3,934 shares of the company’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $41.86, for a total value of $164,677.24. Following the sale, the chief financial officer now directly owns 142,351 shares in the company, valued at $5,958,812.86. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, CFO Bruce N. Jacobs sold 3,934 shares of the business’s stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $41.86, for a total value of $164,677.24. Following the transaction, the chief financial officer now directly owns 142,351 shares of the company’s stock, valued at approximately $5,958,812.86. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jeffrey W. Albers sold 4,385 shares of the firm’s stock in a transaction that occurred on Wednesday, February 21st. The stock was sold at an average price of $39.05, for a total value of $171,234.25. The disclosure for this sale can be found here. Insiders have sold a total of 474,051 shares of company stock valued at $19,624,211 over the last 90 days. 16.67% of the stock is owned by insiders.

Analyst Ratings Changes

Several brokerages have issued reports on KYMR. JPMorgan Chase & Co. raised their price target on Kymera Therapeutics from $34.00 to $47.00 and gave the company an “overweight” rating in a report on Friday, February 23rd. Truist Financial lifted their price objective on Kymera Therapeutics from $41.00 to $54.00 and gave the company a “buy” rating in a report on Friday, March 1st. Bank of America cut Kymera Therapeutics from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $45.00 to $30.00 in a research report on Wednesday, January 3rd. Wolfe Research assumed coverage on shares of Kymera Therapeutics in a research report on Thursday, February 15th. They set a “peer perform” rating for the company. Finally, Stifel Nicolaus raised their target price on shares of Kymera Therapeutics from $35.00 to $55.00 and gave the company a “buy” rating in a report on Friday, February 23rd. Six investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $41.20.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.